Also, indirectly, the use of P2Y2 agonists on the ocular surface to treat dry eye could reduce ocular surface inflammation, but it is necessary to be aware that the anti-inflammatory effect is a consequence of the restorage of aqueous and mucin production. The gene discussed is P2RY2; the disease is Keratoconjunctivitis sicca.